Tempest inks Roche atezolizumab supply deal for Phase 3 liver cancer trial; extends rights plan

Tempest Therapeutics, Inc.

Master clinical supply agreement with Roche for free atezolizumab in planned Phase 3 trial of amezalpat (TPST-1120) in first-line unresectable/metastatic HCC.
Phase 3 study: TPST-1120 + atezolizumab + bevacizumab vs placebo + atezolizumab + bevacizumab; Tempest retains all data from the trial.
Board extended rights plan to expire after 2025 annual meeting or Oct 2026 if stockholders approve, citing stock undervaluation after positive survival data and FDA alignment.
Rights plan triggers at 10% beneficial ownership (15% for passive institutions), with grandfathering for existing holders above threshold.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.